TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Ten-eleven-translocation 2 (TET2) protein is a dioxygenase crucial for DNA demethylation and gene expression regulation.
• Mutations in TET2 are common in hematological cancers, and its activity is impaired in solid tumors, but its role in cancer vulnerability is unexplored.

Purpose of the Study:

• To investigate if TET2 deficiency creates a vulnerability in cancer cells.
• To explore the therapeutic potential of statins in TET2-deficient tumors.

Main Methods:

• Analysis of lipid metabolism changes in acute myeloid leukemia (AML) patients with TET2 deficiency.
• Assessment of statin sensitivity in TET2-deficient tumor cells.
• Investigation of TET2's regulatory role on HMG-CoA synthase 1 (HMGCS1) expression.
• Evaluation of geranylgeranyl diphosphate (GGPP) levels and its role in statin-induced apoptosis.

Main Results:

• TET2 deficiency is linked to altered lipid metabolism in AML.
• Statins significantly sensitize TET2-deficient tumor cells to apoptosis.
• TET2 directly regulates HMGCS1 expression via promoter demethylation; TET2 deficiency downregulates HMGCS1 and the mevalonate pathway.
• Reduced GGPP levels due to statin treatment impair small GTPase function, leading to cell dysfunction.

Conclusions:

• TET2-deficient tumors exhibit a vulnerability exploitable by statins.
• Statins induce apoptosis in TET2-deficient cells by inhibiting the mevalonate pathway and reducing GGPP.
• This study identifies a potential therapeutic strategy using approved statins for TET2-deficient cancers.